143 related articles for article (PubMed ID: 31426129)
61. Megakaryocytic myelosis in a cat.
Michel RL; O'Handley P; Dade AW
J Am Vet Med Assoc; 1976 Jun; 168(11):1021-5. PubMed ID: 931768
[TBL] [Abstract][Full Text] [Related]
62. Myelofibrosis: molecular and cell biological aspects.
Kreipe H; Büsche G; Bock O; Hussein K
Fibrogenesis Tissue Repair; 2012; 5(Suppl 1):S21. PubMed ID: 23259436
[TBL] [Abstract][Full Text] [Related]
63. [Histological diagnosis of Ph-negative myeloproliferative neoplasia. An overview].
Campr V
Cesk Patol; 2011 Jul; 47(3):84-93. PubMed ID: 21887923
[TBL] [Abstract][Full Text] [Related]
64. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
65. Circulating megakaryoblasts in chronic myeloproliferative diseases. An immunoelectron-microscopic study.
Matolcsy A; Majdic O
Acta Haematol; 1990; 84(2):57-63. PubMed ID: 2120886
[TBL] [Abstract][Full Text] [Related]
66. Quantitative interpretation of bone marrow biopsies in MPN-What's the point in a molecular age?
Ryou H; Lomas O; Theissen H; Thomas E; Rittscher J; Royston D
Br J Haematol; 2023 Nov; 203(4):523-535. PubMed ID: 37858962
[TBL] [Abstract][Full Text] [Related]
67. Platelet defects in the myeloproliferative disorders.
Inceman S; Tangün Y
Ann N Y Acad Sci; 1972 Oct; 201():251-61. PubMed ID: 4509685
[No Abstract] [Full Text] [Related]
68. Abnormalities of platelet adenine nucleotides in patients with myeloproliferative disorders.
Nishimura J; Okamoto S; Ibayashi H
Thromb Haemost; 1979 Jun; 41(4):787-95. PubMed ID: 483250
[TBL] [Abstract][Full Text] [Related]
69. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
70. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis.
Martyré MC; Le Bousse-Kerdiles MC; Romquin N; Chevillard S; Praloran V; Demory JL; Dupriez B
Br J Haematol; 1997 May; 97(2):441-8. PubMed ID: 9163611
[TBL] [Abstract][Full Text] [Related]
71. Perfusion parameters analysis of the vertebral bone marrow in patients with Ph¹⁻ chronic myeloproliferative neoplasms (Ph(neg) MPN): a dynamic contrast-enhanced MRI (DCE-MRI) study.
Courcoutsakis N; Spanoudaki A; Maris TG; Astrinakis E; Spanoudakis E; Tsatalas C; Prassopoulos P
J Magn Reson Imaging; 2012 Mar; 35(3):696-702. PubMed ID: 22069235
[TBL] [Abstract][Full Text] [Related]
72. Working classification of chronic myeloproliferative disorders based on histological, haematological, and clinical findings.
Burkhardt R; Bartl R; Jäger K; Frisch B; Kettner G; Mahl G; Sund M
J Clin Pathol; 1986 Mar; 39(3):237-52. PubMed ID: 3457024
[TBL] [Abstract][Full Text] [Related]
73. [Levels of procollagen type III n-terminal peptide (PIIINP) in serum of patients with myeloproliferative syndrome (mps)].
Podolak-Dawidziak M; Wróbel T; Jeleń M
Pol Arch Med Wewn; 1998 Jan; 99(1):24-9. PubMed ID: 9686500
[TBL] [Abstract][Full Text] [Related]
74. Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features.
Ouyang J; Zheng W; Shen Q; Goswami M; Jorgensen JL; Medeiros LJ; Wang SA
Cytometry B Clin Cytom; 2015; 88(4):236-43. PubMed ID: 25557358
[TBL] [Abstract][Full Text] [Related]
75. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.
Medinger M; Skoda R; Gratwohl A; Theocharides A; Buser A; Heim D; Dirnhofer S; Tichelli A; Tzankov A
Br J Haematol; 2009 Jul; 146(2):150-7. PubMed ID: 19466975
[TBL] [Abstract][Full Text] [Related]
76. Assessment of cell proliferation in normal and pathological bone marrow biopsies: a study using double sequential immunophenotyping on paraffin sections.
Pellegrini W; Facchetti F; Marocolo D; Salvi L; Capucci A; Tironi A; Rossi G
Histopathology; 1995 Nov; 27(5):397-405. PubMed ID: 8575729
[TBL] [Abstract][Full Text] [Related]
77. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
Michiels JJ; De Raeve H; Hebeda K; Lam KH; Berneman Z; Schroyens W; Schwarz J
Leuk Res; 2007 Aug; 31(8):1031-8. PubMed ID: 17367853
[TBL] [Abstract][Full Text] [Related]
78. Circulating activated platelets in myeloproliferative disorders.
Wehmeier A; Tschöpe D; Esser J; Menzel C; Nieuwenhuis HK; Schneider W
Thromb Res; 1991 Feb; 61(3):271-8. PubMed ID: 1709309
[TBL] [Abstract][Full Text] [Related]
79. Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification.
Buhr T; Georgii A; Choritz H
Pathol Res Pract; 1993 Mar; 189(2):121-32. PubMed ID: 8321741
[TBL] [Abstract][Full Text] [Related]
80. Some aspects of platelet glucose metabolism in thrombocytosis due to myeloproliferative disorders.
Leoncini G; Maresca M; Balestrero F; Armani U; Piana A
Thromb Res; 1984 May; 34(3):233-9. PubMed ID: 6729778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
